These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8603534)

  • 1. Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders.
    Stoffel MP; Csernok E; Herzberg C; Johnson T; Carroll SF; Gross WL
    Clin Exp Immunol; 1996 Apr; 104(1):54-9. PubMed ID: 8603534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bactericidal permeability increasing protein (BPI-ANCA marked chronic inflammatory bowel diseases and hepatobiliary diseases].
    Schnabel A; Csernok E; Schultz H; Stoffel M; Herzberg C; Carroll SF; Gross WL
    Med Klin (Munich); 1997 Jul; 92(7):389-93. PubMed ID: 9324622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of native and recombinant bactericidal/permeability-increasing proteins (BPI) as antigens for detection of BPI-ANCA.
    Schultz H; Csernok E; Johnston TW; Lockwood CM; Gross WL
    J Immunol Methods; 1997 Jul; 205(2):127-33. PubMed ID: 9294593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK).
    Lindgren S; Nilsson S; Nässberger L; Verbaan H; Wieslander J
    J Gastroenterol Hepatol; 2000 Apr; 15(4):437-42. PubMed ID: 10824890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-neutrophil cytoplasmic autoantibodies (ANCA) to bactericidal/permeability-increasing (BPI) protein recognize the carboxyl terminal domain.
    Dunn AC; Walmsley RS; Dedrick RL; Wakefield AJ; Lockwood CM
    J Infect; 1999 Jul; 39(1):81-7. PubMed ID: 10468134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis.
    Zhao MH; Jones SJ; Lockwood CM
    Clin Exp Immunol; 1995 Jan; 99(1):49-56. PubMed ID: 7813109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies.
    Schultz H; Weiss J; Carroll SF; Gross WL
    J Leukoc Biol; 2001 Apr; 69(4):505-12. PubMed ID: 11310835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of anti-bactericidal/permeability-increasing protein (BPI) and anti-azurocidin in patients with renal disease.
    Yang JJ; Tuttle R; Falk RJ; Jennette JC
    Clin Exp Immunol; 1996 Jul; 105(1):125-31. PubMed ID: 8697620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis.
    Zhao MH; Jayne DR; Ardiles LG; Culley F; Hodson ME; Lockwood CM
    QJM; 1996 Apr; 89(4):259-65. PubMed ID: 8733512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in chinese patients with clinically suspected vasculitis.
    Xin G; Zhao MH; Wang HY
    Clin Diagn Lab Immunol; 2004 May; 11(3):559-62. PubMed ID: 15138182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein and azurocidin.
    Cooper T; Savige J; Nassis L; Paspaliaris B; Neeson P; Neil J; Knight KR; Daskalakis M; Doery JC
    Rheumatol Int; 2000; 19(4):129-36. PubMed ID: 10836522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein.
    Schinke S; Fellermann K; Herlyn K; Reichel PH; Fundke R; Stange EF; Gross WL; Schultz H
    Inflamm Bowel Dis; 2004 Nov; 10(6):763-70. PubMed ID: 15626895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: prevalence and clinical associations.
    Schultz H; Csernok E; Herlyn K; Reichel PH; Moosig F; Cornely OA; Fagerhol MK; Gross WL
    Clin Exp Rheumatol; 2003; 21(6 Suppl 32):S117-20. PubMed ID: 14740437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and clinical significance of anti-lactoferrin autoantibodies in inflammatory bowel diseases and primary sclerosing cholangitis.
    Roozendaal C; Horst G; Pogány K; van Milligen de Wit AW; Kleibeuker JH; Haagsma EB; Limburg PC; Kallenberg CG
    Adv Exp Med Biol; 1998; 443():313-9. PubMed ID: 9781375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease.
    Walmsley RS; Zhao MH; Hamilton MI; Brownlee A; Chapman P; Pounder RE; Wakefield AJ; Lockwood CM
    Gut; 1997 Jan; 40(1):105-9. PubMed ID: 9155585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis.
    Khanna D; Aggarwal A; Bhakuni DS; Dayal R; Misra R
    J Rheumatol; 2003 Jun; 30(6):1248-52. PubMed ID: 12784398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.
    Schultz H; Csernok E; Schuster A; Schmitz TS; Ernst M; Gross WL
    Pediatr Allergy Immunol; 2000 May; 11(2):64-70. PubMed ID: 10893006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro.
    Schultz H; Schinke S; Mosler K; Herlyn K; Schuster A; Gross WL
    Pediatr Pulmonol; 2004 Feb; 37(2):158-64. PubMed ID: 14730661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis after immunisation with bacterial proteins.
    Savige J; Nassis L; Cooper T; Paspaliaris B; Martinello P; MacGregor D
    Clin Exp Rheumatol; 2002; 20(6):783-9. PubMed ID: 12508769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomonas-induced lung damage in cystic fibrosis correlates to bactericidal-permeability increasing protein (BPI)-autoantibodies.
    Carlsson M; Eriksson L; Erwander I; Wieslander J; Segelmark M
    Clin Exp Rheumatol; 2003; 21(6 Suppl 32):S95-100. PubMed ID: 14740434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.